We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Valneva SE (VLA) Common Shares EUR0.15

Sell:€10.63 Buy:€10.67 Change: €0.72 (6.34%)
Market closed |  Prices as at close on 24 May 2022 | Switch to live prices |
Change: €0.72 (6.34%)
Market closed |  Prices as at close on 24 May 2022 | Switch to live prices |
Change: €0.72 (6.34%)
Market closed |  Prices as at close on 24 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Contact details

6 rue Alain Bombard
+33 (2) 28073710

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€1.22 billion
Shares in issue:
107.73 million
Euronext Paris

Key personnel

  • Frederic Grimaud
    Chairman of the Supervisory Board
  • Thomas Lingelbach
    Chairman of the Management Board, President, Chief Executive Officer, Member of the Management Board
  • Franck Grimaud
    President, Chief Business Officer, Member of the Management Board
  • James Sulat
    Independent Vice Chairman of Supervisory Board
  • Peter Buhler
    Chief Financial Officer, Member of the Management Board
  • Perry Celentano
    Interim Chief Operating Officer
  • Andreas Meinke
    Senior Vice President Pre-clinical Research and Development, Member of the Executive Board
  • Vincent Dequenne
    Senior Vice President - Industrial Operations
  • Manfred Tiefenbacher
    Vice President - Finance, Member of the Executive Committee
  • Gerald Strohmaier
    Vice President of Human Resources, Member of the Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.